A look into the neurophysiology behind the runner's high
By Leanne Fogg
Running 13 miles for fun is often thought of as crazy, but for most long distance athletes it is simply another workout that comes with a blissful reward: the runner’s high. Toward the end of a long run, I find myself easily holding a fast pace. My body maintains a smooth rhythm, executing perfect biomechanics as I float along the trail. When in company, I can share this cadence and continue for miles in silence, enjoying the sounds of our synchronized steps. I can find myself in a state of mindlessness, escaping the weight of the stressors of life. This state of tranquility and harmony is referred to as a “runner’s high,” and results after intense exercise.
Reported effects of the runner’s high mirrored the marijuana-induced state many are familiar with. Yes, runners are claiming they can get baked without smoking.
A wave of skepticism triggered the investigation of the runner’s high hypothesis – can exercise alter the neurophysiology of an athlete, leading to pain-relieving and calming effects?
Before we dive into the exercise-induced high investigation, it is helpful to understand the neurophysiological effects marijuana has on the body.
The effects of marijuana are mainly attributed to Δ9-tetrahydrocannabinol (THC) – the primary psychoactive component in the cannabis plant. THC alters the cell-cell communication in the nervous system. A signaling presynaptic neuron will release neurotransmitters, which will bind to their corresponding receptors on the surface of a target postsynaptic neuron. Receptors contain highly specific binding domains that only particular molecules can fit into and elicit the downstream response. Although receptors are designed for specificity, exogenous molecules, like THC, can hijack systems and trigger alterations in many biological processes.
Scientist first discovered these receptors as being sensitive to THC, and appropriately named them the cannabinoid receptors. Cannabinoid receptors come in two flavors: type 1 (CB1R) and type 2 (CB2R). CB1 receptors are primarily located in the central nervous system, as it is one of the most prevalent G protein-coupled receptors in the brain. CB2 receptors are found in tissues throughout the body, and are involved in mediating the immune response.
PET imaging with [11C]MePPEP (an inverse agonist of CB1 receptors), showing the distribution of CB1 receptors throughout the brain (Terry, 2009).
The cannabinoid receptors bind endocannabioids (endogenous neurotransmitters) including arachidonoylethanolamine (anandamide or AEA) and γ-aminobutyric acid (2-AE). Anandamide, meaning “blissful amide,” is the main agonist (effector molecule) of CB1 receptors, leading to alterations in appetite, mood, and pain sensation.
Although receptors are highly specific, CB1 receptor activation can result through the binding of an endocannabinoid or THC. CB1 receptor binding occurs through the recognition of a hydrocarbon chain motif that AEA, 2-AE, and THC all share.
|CB1 receptor agonists (highlighted: binding motifs)|
Endocannabinoid receptors are a type of G protein – they are protein receptors that span the membrane of a cell and trigger a signal transduction pathway upon binding of a specific molecule. CB1 receptors are located at the axon terminals of a presynaptic neuron (the “end” of a signaling neuron). Binding to the CB1 receptor will prohibit the release of neurotransmitters, inhibiting the signal from being passed to the postsynaptic neuron (the target neuron will not receive the signal). This process naturally occurs in our bodies and is known as depolarization-induced-suppression inhibition (DSI).
|Depolarization-induced-suppression inhibition (DSI) induced through binding of CB1 receptor|
Whoa there... DSI? Let’s break this down:
Depolarization-induced: This effect is triggered upon depolarization of a neuron (when an action potential arrives, the cell depolarizes, becoming more positively charged on the inside).
Suppression: CB1 receptors are located on GABAergic neurons (neurons that release the neurotransmitter γ-aminobutyric acid, or GABA). GABA is an inhibitory neurotransmitter, suppressing the target cell from depolarization.
Inhibition: GABA neurotransmitter release is inhibited through the activation of CB1 receptors.
All together now: When postsynaptic neurons become depolarized, endocannibinoids are released and travel retrograde to CB1 receptors on a GABAergic neuron. Activation of the CB1 receptor then leads to the inhibition of GABA release.
CB1 receptor activation leads to the inhibition of adenylyl cyclase (the enzyme that synthesizes cAMP), and subsequent decrease in calcium concentrations. Low amounts of calcium prevent GABA-containing vesicles from fusing out of the cell. DSI alters neuronal communication, changing the way we perceive pain and stress.
So how is this all connected to the runner’s high hypothesis? It has been demonstrated that endocannabinoid system (ECS) activation can be induced upon exercise in humans.
|Circulating AEA levels in human subjects were significantly higher only after intense running or cycling (Sparling, 2003).|
A comparison between cursorial (an animal adapted for running) and non-cursorial mammals revealed elevated AEA levels after exercise in dogs and humans while no significant increase in ferrets.
|A) Plasma AEA levels before (white) and after (black) high intensity running; B) plasma AEA levels before (white) and after (black) walking, (Raichlen, 2011).|
This study sheds light on possible evolutionary benefits of ECS activation. Allowing animals that have pushed themselves to their limit to enter a euphoric state might allow them to better survive - maybe running even farther than they anticipated to catch prey, or even running from a predator. ECS activation could be a result of a mechanism that promotes endurance in running mammals.
Circulating AEA has been demonstrated to correlate with the subsequent binding to CB1 receptors in specific regions throughout the brain, including the frontolimbic brain areas associated with mood. Euphoric levels reported by subjects correlated with CB1 receptor binding in the brain.
Activation of ESC has also provided evidence of reducing pain sensitivity and sedation, further supporting the runner's high hypothesis.
|fMRI scans before and after exercise show a reduction in pain processing in the brain (Scheef, 2012).|
Exercise increases AEA levels, which in turn act on CB1 receptors, leading to DSI. It is through this mechanism that we can enter euphoric states - whether that be smoking dope or going for a long run on the central coast... I prefer the latter.
Stay tuned for more on the endocannabinoid system and the promising future in the treatment of breast cancer, depression, and obesity.
Alger, B.E., Endocannabinoid at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know, The Journal of Physiology 590(10):2203-2212.
Boecker, H., T. Sprenger, M.E. Spilker, G. Henriksen, M. Koppenhoefer, K.J. Wagner, M. Valet, A. Berthele, T.R. Tolle. 2008. The runner's high: opioidergic mechanism in the human brain, Cerebral Cortex 18:2523-2531.
Raichlen, D. A., A.D. Foster, G.L. Gerdeman, A. Seiller, A. Giuffrida. 2011. Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high, The Journal of Experimental Biology 215:1331-1336.
Scheef, L., J. Jankowski, M. Daamen, G. Weyer, M. Klingenberg, J. Renner, S. Mueckter, B. Schurmann, F. Musshoff, M. Wagner, H.H. Schild, A. Zimmer, H. Boecker, An fMRI study on the acute effect of exercise on pain processing in trained athletes, International Association for the Study of Pain 153:1702-1714.
Sparling, P.B., A. Giuffrida, D. Piomelli, L. Rosskopf, A. Dietrich. 2003. Exercise activates the endocannabinoid system, NeuroReport 14(17):2209-2211.
Terry, G.E., J. Liow, S.S. Zoghbi, J. Hirvonen, A.G. Farris, A. Lerner, J.T. Tauscher, J.M. Schaus, L. Phebus, C.C. Felder, C.L. Morse, J.S. Hong, V.W. Pike, C. Halldin, R.B. Innis, Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand, Neuroimage 48(2):362-370.